Satraplatin for Patients With Metastatic Breast Cancer (MBC)
To determine the objective response rate (ORR) of oral satraplatin in patients with Metastatic Breast Cancer.
Metastatic Breast Cancer
DRUG: Satraplatin
To determine the objective response rate (ORR) of oral satraplatin in patients with metastatic breast cancer, 1 year
To determine duration of response, 6 weeks|To determine progression-free survival (PFS), 1 year|To determine 1-year survival, 1 year|To evaluate the toxicities of satraplatin in MBC patients, 6 weeks|In patients with nonmeasurable MBC, to assess the clinical utility of serum CA27.29 (or CA15.3) and circulating tumor cells as predictors of time to disease progression, 6 weeks
This is a Phase II open label, nonrandomized study for patients with metastatic breast cancer.

WHAT IS SATRAPLATIN:

Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.